Orexin Receptor 2 Agonist Program for Sleep-Wake Disorders
A potential best-in-class treatment for sleep-wake disorders
Orexin agonists have the potential to address the underlying cause of narcolepsy type 1 (NT1) and bring potentially transformative treatment options to enhance patient lives in NT1, narcolepsy type 2 (NT2), idiopathic hypersomnia (IH) and other potential sleep-wake disorders. However, there exists a significant gap in the development of orexin agonists, attributed to their complex medicinal chemistry. At Centessa, we aim to overcome this obstacle by leveraging structural biology techniques and structure-based drug design to help guide the design of small molecule orexin agonists.
We aim to address these unmet needs with our lead orexin agonist drug candidate, ORX750.
Drug Candidate
ORX750 is an investigational orally administered, highly potent, and selective orexin receptor 2 (OX2R) agonist.
ORX750 is designed to activate orexin signaling in the brain and treat the underlying cause of NT1.
ORX750 was designed by Centessa using structure-based drug design capabilities, high-resolution protein crystallography, and cryo-EM.
Novel MOA
At Centessa, we are exploring additional molecules for potential expansion opportunities into a range of sleep-wake disorders and broader neurological indications.
ORX750 is an investigational agent that has not been approved by the FDA or any other regulatory authority.
References: 1. Mahoney CE, Cogswell A, Koralnik IJ, Scammell TE. The neurobiological basis of narcolepsy. Nature Review Neuroscience. 2019;20(2):83-93. Nixon JP, Mavanji V, Butterick TA, Billington CJ, Kotz CM, Teske JA. Sleep disorders, obesity, and aging: the role of orexin. Ageing Research Reviews. 2015;20:63-73. 2. Centessa Pharmaceuticals. Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750’s Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders. Published October 25, 2023. Accessed November 1, 2023. https://investors.centessa.com/news-releases/news-release-details/centessa-pharmaceuticals-announces-preclinical-data-supporting-.
Lorem Ipsum
Lorem ipsum dolor sit amet, consectetur adipiscing elit. In ut sodales augue, a placerat felis. Cras nec mauris ut metus fringilla eleifend. Sed suscipit diam non arcu condimentum imperdiet.
Aenean facilisis ligula lectus, quis porttitor tortor vehicula ac.
Quisque ultricies ex at malesuada rutrum. Proin tempor diam et turpis lacinia eleifend.
Lorem Ipsum
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Integer et massa interdum, mollis ante at, luctus lorem. Ut tincidunt vulputate volutpat. In ut sodales augue, a placerat felis.
References: 1. Mahoney CE, Cogswell A, Koralnik IJ, Scammell TE. The neurobiological basis of narcolepsy. Nature Review Neuroscience. 2019;20(2):83-93. Nixon JP, Mavanji V, Butterick TA, Billington CJ, Kotz CM, Teske JA. Sleep disorders, obesity, and aging: the role of orexin. Ageing Research Reviews. 2015;20:63-73. 2. Centessa Pharmaceuticals. Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750’s Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders. Published October 25, 2023. Accessed November 1, 2023. https://investors.centessa.com/news-releases/news-release-details/centessa-pharmaceuticals-announces-preclinical-data-supporting-.
